Clinical trials: Lesion Skin
Secondarily Infected Traumatic Lesions (SITL), Impetigo
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic…
- Trial name
- NCT00758862
- Testing
- 2% TD1414 Cream
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- LEO Pharma
Pigmented Skin Lesion of Suspected Benign Nature
A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal
To evaluate the safety and efficacy of an investigational version of the Cutera enlightenTM laser that offers multiple wavelengths for removal of benign pigmented lesions.
- Trial name
- NCT02635880
- Testing
- Investigational Enlighten Device
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Hidradenitis Suppurativa
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNSHINE (NCT03713619)
- Testing
- secukinumab
- Where
- 111 sites in United States, Argentina and 27 more
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Erythema, Edema
Human Repeat Insult Patch Test to Evaluate Personal Lubricants
The purpose of this test is to evaluate the sensitizing potential of a personal lubricant, as a result of repeated occlusive patch.
- Trial name
- HRIPT (NCT02737631)
- Testing
- "Chameleon" Personal Lubricant
- Where
- United States
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Keratosis, Actinic
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
The primary purpose for this study is to assess recurrence of Actinic Keratosis in participants achieving complete response treated in earlier study.
- Trial name
- NCT04269395
- Testing
- MAL Cream, Vehicle cream
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 125 people
- Sponsor
- Galderma R&D
Rosacea
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of inflammatory lesions rosacea
- Trial name
- NCT02795117
- Testing
- Ivermectin, Ivermectin (reference)
- Volunteers
- 486 people
- Sponsor
- Padagis LLC
Keratosis
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands.
- Trial name
- NCT00116649
- Testing
- imiquimod cream
- Where
- 32 sites in United States
- Volunteers
- 551 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Case Collection Study to Support Digital Mammography Image Software Change
The primary objective of this study is to compare image processing software to support a new image processing software application for a full-field digital mammography (FFDM) system.
- Trial name
- LIP2SIP (NCT00756496)
- Testing
- Mammography screening and diagnosis
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- Siemens Medical Solutions USA - CSG
Actinic Keratosis
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
- Trial name
- NCT02632110
- Testing
- ALA, Topical Solution Vehicle, IBL 10 mW
- Where
- 8 sites in United States
- Volunteers
- 137 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Erythema, Edema
Repeated Insult Patch Test of Personal Lubricants
Determine the ability of the study material (personal lubricant) to cause sensitization by repeated topical application to the skin of humans under controlled patch test conditions.
- Trial name
- NCT02297841
- Testing
- Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Systemic Sclerosis
Open-Label Study of Oral Treprostinil in Digital Ulcers
This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects…
- Trial name
- DISTOL-EXT (NCT00848107)
- Testing
- treprostinil diethanolamine
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 115 people
- Sponsor
- United Therapeutics
Skin Care
To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test
To assess the irritation potential of four prototype daily defense serum formulations after 24 (± 2) hours under semi-occlusive patch application to the skin of healthy volunteers.
- Trial name
- NCT03233009
- Testing
- Experimental Daily Defense Serum A, Experimental Daily Defense Serum C, Experimental Daily Defense Serum G
- Where
- 2 sites in Brazil
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Inherited Epidermolysis Bullosa
Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)
The purpose of this study was to compare intra-individually the reepithelialization of skin lesion(s) in inherited Epidermolysis bullosa (either 1 wound ≥10 cm2 and ≤200 cm2 in size divided in 2 equal halves or 2 comparable…
- Trial name
- NCT01294241
- Testing
- Oleogel-S10, Mepilex® soft silicone faced polyurethane foam dressing
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Birken AG
Restless Legs Syndrome, End-Stage Renal Disease
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
This is a sleep laboratory study to evaluate the efficacy and safety of Rotigotine in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis.
- Trial name
- NCT01537042
- Testing
- Rotigotine
- Where
- 15 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- UCB BIOSCIENCES GmbH
Impetigo, Secondarily Infected Traumatic Lesions
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen…
- Trial name
- NCT00626795
- Testing
- TD1414 2% cream, Bactroban® (mupirocin) 2% cream
- Where
- 2 sites in United States, South Africa
- Volunteers
- 773 people
- Sponsor
- LEO Pharma
Erythema, Maceration
Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions
This study will evaluate the efficacy of the DriGo skin protectant textile (SPT) to manage erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor associated with skin folds (henceforth…
- Conditions
- Erythema, Maceration, Lesion Skin, Skin Folds
- Trial name
- NCT05742347
- Testing
- DriGo Skin Protectant Textile
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Medline Industries
Skin Care
To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Participants
The objective of this clinical study is to assess the irritation and sensitisation potential of a cosmetic test product after repeated semi-occlusive patch applications to healthy human participants by following a conventional…
- Trial name
- NCT03175562
- Testing
- Facial micellar cleanser, Saline Solution: Sodium Chloride (NaCl; 0.9%)
- Where
- Brazil
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
- Trial name
- SKINDLE (NCT01597050)
- Testing
- R932333
- Where
- 15 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Rigel Pharmaceuticals
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals